ard ratio 0.66, range 0. 43-1.03). An interaction model illustrated that KRAS p.G12C was associated with unfavorable outcome when treated with oxaliplatin plus cetuximab. Conclusion: The present analysis suggests that KRAS codon 12 mutation may not represent a homogeneous entity in mCRC when treated with cetuximab-based first-line therapy.
tor receptor (EGFR) causes activation of the downstream signal transduction cascade to the nucleus. In the first step, the intracellular tyrosine kinase domain of the EGFR is phosphorylated which in turn induces a transient activation of the RAS protein. While in its inactive state, RAS is bound to guanosine diphosphate (GDP), activation occurs by the conversion of GDP to GTP [1, 2] .
Mutations of the KRAS gene are described to occur in approximately 40% of metastatic colorectal cancers. The mutations of KRAS are point mutations and are mostly ( 1 90%) detected in codon 12 (approx. 80%) and codon 13 (approx. 20%) and are far less frequent in other codons like codon 61 [2] [3] [4] [5] [6] . In some studies, different types of KRAS mutations, mostly in codon 13, were reported to be associated with a more aggressive biology concerning the risk of relapse after initial surgery was performed for colorectal cancer [7, 8] . For metastatic colorectal cancer (mCRC), mutations in the KRAS proto-oncogene have been identified as determinants of poor response to anti-EGFR antibodies such as cetuximab and panitumumab leading to an exclusion of affected patients from anti-EG-FR therapy [9] [10] [11] [12] [13] . However, several recent studies did not identify wild-type KRAS alone to be a strong predictor of response to anti-EGFR antibodies [14] [15] [16] .
In patients with KRAS mutated tumors, the combination of FOLFOX plus anti-EGFR-directed antibodies showed trends to be associated with shorter overall survival (OS) when compared to FOLFOX alone in the PRIME study (15.5 vs. 19 .3 months; p = 0.068) and in the smaller OPUS study (13.4 vs. 17.5 months; p = 0.2) [11, 17] .
Disappointing outcomes in patients undergoing treatment with anti-EGFR antibodies and chemotherapy were mostly observed in studies using an oxaliplatin-based chemotherapy backbone, while this was not the case in studies using irinotecan-based chemotherapy backbones [10, 18] . Therefore, it has been hypothesized that an unknown mechanism of inhibitory interaction may exist for the combined use of anti-EGFR agents and oxaliplatin in patients with KRAS mutant mCRC.
The concept of KRA S mutant tumors as a uniform entity generally resistant to anti-EGFR antibodies was first questioned by de Roock and coworkers [19] . In a recent report based on preclinical and clinical investigations, this group indicated that KRAS p.G13D mutant mCRC compared to other KRAS mutant tumors is associated with unfavorable outcome receiving best supportive care, but with a longer OS and progression-free survival (PFS) when treated with cetuximab.
These findings are further supported by studies investigating the role of KRAS mutations in the risk of relapse and death after primary resection of colorectal cancer. A decade ago, KRAS mutation in codon 13 was identified as a risk factor of poor outcome [7, 8, 20] . Other authors described codon 12 mutation (p.G12V) as a marker of a highly aggressive disease [8, 21] .
In the present analysis, we investigate patients with mCRC exclusively characterized by a mutation in KRAS codon 12 . The study aims to analyze the question whether subtypes of KRAS codon 12 mutation have an impact on treatment outcome.
Methods

KRAS Mutation Detection
All tumor samples were evaluated using validated methods of high sensitivity for KRAS diagnostics [22, 23] . In terms of the AIO KRK-0104 and the AIO KRK-0306 trial, KRAS testing was performed in a German reference laboratory for KRAS analysis (Department of Pathology, University of Munich, Munich, Germany). Detection of mutations in codons 12 and 13 of the KRAS proto-oncogene was performed by pyrosequencing using Qiagen's PyroMark Gold kits together with a Q24 pyrosequencer device [5] . This procedure resulted in a specificity of 0.98 and a sensitivity of 0.99 for the detection of mutations in the KRAS proto-oncogene [5, 15, 18, 24] . The tumor samples belonging to the Central European Cooperative Oncology Group (CECOG) trial were retrospectively tested for KRAS by an allele-specific real-time polymerase chain reaction assay which demonstrated comparable precision in KRAS testing (DxS Ltd., Manchester, UK) [22, 23, 25] .
Treatment Schedules
The AIO KRK-0104 study was designed as an open-label, randomized phase II study as previously reported by Moosmann et al. [15] and Modest et al. [18] . It was conducted at 35 centers in Germany. In both study arms, cetuximab was given at an initial dose of 400 mg/m 2 as a 120-min infusion, followed by weekly infusions of 250 mg/m 2 over 60 min. Patients in arm A received chemotherapy with CAPIRI (i.e. oral capecitabine 800 mg/m 2 twice daily on days 1-14, followed by a 1-week rest period plus irinotecan 200 mg/m 2 as a 30-min intravenous infusion on day 1). In patients 1 65 years, doses were further reduced by 20%. Patients in arm B received chemotherapy with CAPOX (i.e. capecitabine 1,000 mg/m 2 twice daily on days 1-14, followed by a 1-week rest period plus oxaliplatin 130 mg/m 2 as a 120-min intravenous infusion on day 1). Treatment cycles were repeated every 3 weeks until disease progression or unacceptable toxicity [15] .
The ongoing AIO KRK-0306 study was designed as a randomized study and is presently conducted at 177 centers in Germany and Austria. This trial compares FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab. Following an amendment, the study was closed for patients with KRAS mutant mCRC in 2009. Therefore, only patients with KRAS mutated mCRC could be analyzed in the present analysis. As described before, only patients included in the cetuximab arm were evaluated. FOLFIRI was applied as previously reported by Tournigand and coworkers [26] . Irinotecan (180 mg/m 2 ) was given as a 60-min infusion followed by fo-linic acid (400 mg/m 2 ), as a 120-min infusion and by an intravenous bolus of 5-fluorouracil (5-FU; 400 mg/m 2 ) and 5-FU (2,400 mg/m 2 ) applied as a 46-hour continuous infusion. The regimen was repeated every 2 weeks. Cetuximab was given at an initial dose of 400 mg/m 2 as a 120-min infusion, followed by weekly infusions of 250 mg/m 2 over 60 min. Treatment was performed until disease progression or unacceptable toxicity [24] .
The CECOG study was a two-arm randomized multicenter, open-label, parallel-group phase II study involving 28 participating centers across 13 countries (CECOG/CORE1.2.001). Eligible patients were centrally randomized 1: 1, using a minimization technique, stratifying patients according to study site, the number of organs involved and prior neoadjuvant/adjuvant therapy. Patients received cetuximab (400 mg/m 2 initial infusion on day 1, then 250 mg/m 2 weekly) and were then placed either in arm A or ) with the 5-FU/ FA regimen described (FOLFIRI) [25] .
Patients
The present analysis investigated 119 mCRC patients with a confirmed KRAS mutation in codon 12 that received cetuximabbased first-line therapy for mCRC. All patients were treated within the AIO KRK-0104 (NCT00254137; 41 patients), the AIO KRK-0306 (NCT00433927; 39 patients) or the CECOG trial (39 patients). A total of 62 patients received FOLFIRI, while 16 patients were treated with FOLFOX. Further 27 patients received CAPIRI and 14 patients CAPOX. The protocols of the clinical trials were approved by an independent ethics committee and governmental authorities. The trials were conducted in accordance with the Declaration of Helsinki (1996) . All patients provided written and oral informed consent to be treated within the clinical trials.
Endpoints
The present investigation was performed as an exploratory analysis. Radiological tumor response (complete remission, partial remission, stable disease, progressive disease) was assessed according to RECIST criteria. Response evaluation was performed at 6-to 8-week intervals. PFS was defined as the interval between randomization and first documentation of progression or death; OS was calculated as the time between randomization and death due to any reason. Patients alive were censored at the last time point of patient contact.
Statistical Analysis
Data were summarized by adequate measures of location and variation for continuous variables and by proportions for discrete variables. Adequate tests for discrete data ( 2-test) were used. Survival data were described by using the Kaplan-Meier estimator. Differences in survival between the groups were tested by Cox regressions. Differences in OS and PFS were modelled using Cox proportional hazards regression where a treatment-covariate interaction (irinotecan vs. oxaliplatin and codon 12 mutation subtype) was included. The resulting hazard ratios were tested by the Wald test. All statistical tests were performed two-sided, and a p value ! 0.05 was considered statistically significant. All statistical analyses were performed using R (version 2.13.2) and IBM SPSS (version 19).
Results
Study Population
This exploratory analysis includes 119 patients who received first-line treatment for mCRC. Characteristics of the patients analyzed in this study do not indicate significant differences regarding age, sex, ECOG status or primary disease sites when compared between the different subgroups. The frequencies of KRAS codon 12 mutations within our study population were 44 p.G12D (37%), 36 p.G12V (30%), 14 p.G12A (12%), 13 p.G12C (11%), 8 p.G12S (7%) and 4 p.G12R (3%; table 1 ).
Impact of Codon 12 Subgroups on Parameters of Treatment Efficacy
Patients with KRAS codon 12 mutated tumors showed significantly different response rates depending on the single mutation. Mutations in position 35 (p.G12D, p.G12A, p.G12V) showed response rates of at least 40%, while mutations in position 34 (p.G12C, p.G12S, p.G12R) were associated with lower response rates of ! 20%. Correspondingly, PFS reached durations from 4.9 (p.G12C) to 9.8 months (p.G12A; table 2 ).
Median OS observed in this pooled analysis revealed marked differences between the single mutations. While patients with KRAS p.G12D mutant mCRC showed an OS of 23.3 months, survival observed in patients with tumors bearing other KRAS codon 12 mutations was generally shorter, reaching 14-18 months ( table 2 ; figure 1 ).
Interaction Tests: PFS and OS
PFS was illustrated by an interaction model including irinotecan versus oxaliplatin and the KRAS mutation as possible parameters. If all KRAS mutations were taken into account and p.G12D was defined as the 'reference mutation', a significant negative interaction (p = 0.03) was found in patients with KRAS p.G12C mutant tumors who were treated with cetuximab-and oxaliplatin-containing regimens. This interaction test modeling OS instead of PFS again illustrated the negative interaction in patients with KRAS p.G12C mutant tumors undergoing cetuximab plus oxaliplatin-based first-line therapy (p = 0.002; table 3 ).
Discussion
Mutations of the KRAS gene are observed in approximately 40% of sporadic colorectal cancers [3, 6] . Generally, metastatic colorectal tumors are tested only for mu- . These mutations lead to a base exchange which in turn codes for different amino acids at the catalytic site of the resulting KRAS protein. Although, the intrinsic level of KRAS-GTPase activity may be variably affected, the described clinical impact of the specific mutation is not consistent between different studies and tumor stages [19, 27, 28] .
Several studies performed in chemotherapy-refractory mCRC patients have indicated that anti-EGFR agents are not effective when tumors bear KRAS mutations [29] [30] [31] [32] [33] . Subsequently, also in first-line studies, no benefit of anti-EGFR treatment was observed in patients with KRAS mutant tumors [10, 11, 17] . Therefore, KRAS mutant mCRCs were generally regarded as resistant to anti-EG-FR treatment. This assumption was maintained until recently, when a study performed in pretreated patients demonstrated that also tumors with a c.38G ] A (p.G13D) mutation in codon 13 responded to treatment with cetuximab [19] .
Our pooled analysis focused on KRAS codon 12 mutations and was designed to perform a comparative subgroup analysis of the observed mutations.
In our study, outcome parameters of patients with tumors bearing a p.G12D mutation were generally more favorable compared to other mutations. A median OS of 23.3 months observed for this subgroup compares well to the survival of patients with KRAS wild-type tumors, as shown in various other trials [10, 11, 17] . It might be important to note that the majority of patients with KRAS p.G12D mutant mCRC in our pooled analysis were treated with cetuximab plus irinotecan-based chemotherapy. By contrast, no prognostic impact of p.G12D mutation compared to other KRAS mutations in patients with mCRC receiving first-line treatment with FOLFOX plus panitumumab/placebo was described by a recent report [34] . Taken together, these observations may point to a heterogeneous sensitivity of KRAS codon 12 mutant tumors to the combined use of chemotherapy plus anti-EGFR antibody or to a prognostic impact of the mutation position. Our pooled analysis might be biased by the fact that the majority of patients received irinotecan-based regimens.
The PRIME trial, comparing FOLFOX to FOLFOX plus panitumumab, demonstrated that patients with KRAS mutant tumors have a better outcome when treated with FOLFOX alone compared to FOLFOX plus panitumumab. This difference was nearly significant [17] . A similar effect was observed in the OPUS trial (FOLFOX vs. FOLFOX plus cetuximab), although no statistical significance was reached either [11] . However, the CRYSTAL trial, using irinotecan-based chemotherapy, did not describe any differences in terms of OS in patients with KRAS mutant tumors when cetuximab was added to FOLFIRI [10] . Therefore, interactions between some KRAS mutations and oxaliplatin might be suspected to cause negative effects in patients with mCRC. In our dataset, an interaction model in which p.G12D was used as the 'reference mutation' demonstrated that p.G12C mutation correlates with poor outcome when treated with oxaliplatin-based first-line treatment. This finding might be supported by the translational analysis of the PRIME trial, which describes KRAS p.G12C mutations to correlate with a poor prognostic impact on PFS and OS (OS not significant) when treated with FOLFOX alone compared to other KRAS mutations [34] .
Due to the limited number of patients involved in the oxaliplatin-treated subgroup, conclusions must be drawn very carefully. However, our observations suggest that the combination of anti-EGFR-directed agents with specific chemotherapeutics may be an important determinant of outcome with different effects in the respective mutation subgroup. Based on the present data, it could be hypothesized that the poor outcome of patients with KRAS codon 12-34 mutated tumors, especially those with p.G12C mutation, may be an important factor determining the disappointing survival of KRAS mutant patients exposed to oxaliplatin plus anti-EGFR antibodies [11, 17] . Although our retrospective evaluation only allows the formation of hypotheses, future studies evaluating drugs targeting the MAP kinase pathway in patients with KRAS mutant tumors may expect differences within the KRAS codon 12 mutant group. Finally, the influence of the three single studies on our results cannot be evaluated properly due to the small numbers of patients in our subgroups observed in each trial.
In conclusion, this analysis suggests that KRAS codon 12 mutations are associated with variable outcomes in patients with mCRC. This survival variety might be influenced by the chemotherapy combined with cetuximab as first-line regimen. Prospective trials will have to clarify the sensitivity of KRAS codon 12 subgroups to chemotherapy.
